drugset / Trial / NCT03897439

Individualizing Pharmacotherapy for African American Smokers

NCT03897439 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

Improving cessation outcomes for African American smokers through the use of novel, empirically-based strategies is a national health priority. In the vast majority of smoking cessation studies and in clinical practice, when smokers are provided a medication to help them quit, they are expected to continue that medication regardless of how well it is working. This study will assess whether African Americans smokers respond better if they continue with a single treatment or if their treatment is changed when that treatment is not working.

Timeline

Start
2019-05-01
Primary completion
2021-11-30
Completion
2022-01-30

Outcome

Missed primary endpoint

paper verified 7-day abstinence was not significantly different by treatment group at 12 weeks PMID 37338906 ↗

paper 95% CI, 0.89-2.80; P = .12 PMID 37338906 ↗

paper adaptation to varenicline and/or bupropion + NP after failure of NP monotherapy did not significantly improve abstinence rates PMID 37338906 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 150 mg —
Subject Varenicline Small molecule 1 mg —
Background Nicotine patch Unknown 21 mg Other

Indications

No indication recorded.